Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesEffect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy
Seminars in Arthritis and Rheumatism, 06/30/09
Barnabe C et al. - Anti-TNFα therapies are reported to have beneficial effects on bone density and bone turnover markers. However, retrieved studies in this review were heterogeneous with regards to patients studied, underlying risks for osteoporosis, and supplemental therapy, which may limit the findings of the true effect of anti-TNFα therapy on bone.
Methods- Review of current literature reporting on:
- Effect of anti-TNFα on bone density as measured by DEXA at the lumbar spine and hip
- Effect on markers of bone turnover and resorption, in pts using anti-TNFα for rheumatic disease indications
- PubMed search, as well as manual search of related articles and references of articles retrieved
- Studies pertaining to the effect of anti-TNFα therapy on BMD and bone turnover markers were included
- In RA, 4 studies (238 pts) showed a stabilization or increase of BMD at the spine or hip with only 1 negative study in 48 pts
- In spondyloarthopathies, 3 studies (75 pts) all demonstrated an increase in BMD at the lumbar spine and at the hip
- Changes in markers of bone formation and bone resorption were heterogeneous but in general represented a modest increase in formation and decline in resorption
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: The Japanese Population-based Osteoporosis (JPOS) Cohort Study
Osteoporosis International, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor